A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.

Inclusion Criteria:

• Symptomatic blepharitis.

• At least 6 years of age.

• Eyelid collarette count (minimum score 2).

• Willing and able to follow all instructions and attend all study visits.

• Able to avoid prohibited medication for the duration of the study.

• Patients can willingly provide consent or have a legal authorized representativeprovide consent on the informed consent (IC) Form.

Exclusion Criteria:

• Women with confirmed pregnancies.

• Utilizing any current medical therapy for the eye.

• History of allergic reaction to spinosad or any formulation component.

• Patients using eyelid hygiene or other treatment(s) for blepharitis within 14 daysof screening.

• History of ocular surgery within the past 1 year.

• Presence of other ocular diseases that may affect study outcomes (CornealDystrophies, Salzmanns disease, Severe dry eye, Keratoconus, Glaucoma filteringblebs).

• Use of investigational drug, chronic glaucoma medications, steroid.

• Uncontrolled systemic disease.

• Acute or chronic illness that would confound study results.